Systemic sclerosis & Raynaud's
Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study
Authors' conclusion
In SSc patients with early PVD, the development of PAH and/or deterioration was less frequent among patients receiving ambrisentan
Study context
- Population
- Systemic sclerosis (SSc) patients with mild pulmonary vascular disease who participated in the EDITA study and received regular follow-up4 of 38 lost to follow-up
- Participants
- 34 patients
- Comparison
- Ambrisentan vs no pulmonary arterial hypertension (PAH) therapy
- Ambrisentann = 19
- No PAH medicationn = 15reference
- Primary endpoint
- Whether continued ambrisentan vs no treatment prevented the development of PAH according to the new definition
Methodological detailslong-term follow-up
- Long-term follow-up
Primary result
As reported in the abstract
PAH (new definition), catheterised patients · mean follow-up 2.59 ± 1.47 years
Ambrisentan
1 of 17
events
No PAH medication
6 of 12
events
P < 0.0001
Further findings
| Outcome | Ambrisentan | No PAH medication | P value |
|---|---|---|---|
| Change in mPAP, catheterised patients | −1.53 ± 2.53 mmHg | 1.91 ± 2.98 mmHg | P = 0.003 |
Original publication
Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study. Arthritis Res Ther. Published 18 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →